EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improving Maximum Tolerated Dose Selection in Model‐Assisted Designs for Phase I Trials Through Bayesian Dose–Response Model

Rentaro Wakayama, Tomotaka Momozaki iD, Shuji Ando iD

Pharmaceutical Statistics · 2025

DOI: 10.1002/pst.70046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Rentaro Wakayama und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Information Sciences, Graduate School of Science and Technology, Tokyo University of Science, Chiba, Japan. Hauptthemen laut MEDLINE: Maximum Tolerated Dose, Clinical Trials, Phase I as Topic, Research Design, Models, Statistical. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Model‐assisted designs have garnered significant attention in recent years due to their high accuracy in identifying the maximum tolerated dose (MTD) and their operational simplicity. To identify the MTD, they employ estimated dose limiting toxicity (DLT) probabilities via isotonic regression with pool‐adjacent violators algorithm (PAVA) after trials have been completed. PAVA adjusts independently estimated DLT probabilities with the Bayesian binomial model at each dose level using posterior variances ensure the monotonicity that toxicity increases with dose. However, in small sample settings such as Phase I oncology trials, this approach can lead to unstable DLT probability estimates and reduce MTD selection accuracy. To address this problem, we propose a novel MTD identification strategy in model‐assisted designs that leverages a Bayesian dose–response model. Employing the dose–response model allows for stable estimation of the DLT probabilities under the monotonicity by borrowing information across dose levels, leading to an improvement in MTD identification accuracy. We discuss the specification of prior distributions that can incorporate information from similar trials or the absence of such information. We examine dose–response models employing logit, log–log, and complementary log–log link functions to assess the impact of link function differences on the accuracy of MTD selection. Through extensive simulations, we demonstrate that the proposed approach improves MTD selection accuracy by more than 10% in some scenarios and by approximately 6% on average compared to conventional approach. These findings indicate that the proposed approach can contribute to further enhancing the efficiency of Phase I oncology trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Maximum Tolerated DoseClinical Trials, Phase I as TopicResearch DesignModels, StatisticalAntineoplastic AgentsBayes TheoremHumansDose-Response Relationship, DrugAlgorithmsComputer Simulation

Stichwörter der Autor:innen

Bayesian inferenceBayesian optimal interval designdose findingisotonic regressionmaximum tolerated dose

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Information Sciences, Graduate School of Science and Technology, Tokyo University of Science, Chiba, Japan.
  • Department of Information Sciences, Faculty of Science and Technology, Tokyo University of Science, Chiba, Japan.

ORCID-Profile: Tomotaka Momozaki, Shuji Ando

Zitieren

APA

Wakayama, R., Momozaki, T., & Ando, S. (2025). Improving Maximum Tolerated Dose Selection in Model‐Assisted Designs for Phase I Trials Through Bayesian Dose–Response Model. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70046

Vancouver

Wakayama R, Momozaki T, Ando S. Improving Maximum Tolerated Dose Selection in Model‐Assisted Designs for Phase I Trials Through Bayesian Dose–Response Model. Pharmaceutical Statistics. 2025. doi:10.1002/pst.70046

BibTeX
@article{Wakayama2025,
  author = {Wakayama, Rentaro and Momozaki, Tomotaka and Ando, Shuji},
  title = {Improving Maximum Tolerated Dose Selection in Model‐Assisted Designs for Phase I Trials Through Bayesian Dose–Response Model},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  doi = {10.1002/pst.70046}
}
Kostenlos starten →